Emerald Mutual Fund Advisers Trust decreased its stake in Puma Biotechnology Inc (PBYI) by 33.46% based on its latest 2018Q3 regulatory filing with the SEC. Emerald Mutual Fund Advisers Trust sold 105,400 shares as the company’s stock declined 49.57% with the market. The institutional investor held 209,624 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $9.61M, down from 315,024 at the end of the previous reported quarter. Emerald Mutual Fund Advisers Trust who had been investing in Puma Biotechnology Inc for a number of months, seems to be less bullish one the $891.98 million market cap company. The stock decreased 6.44% or $1.61 during the last trading session, reaching $23.39. About 1.10M shares traded. Puma Biotechnology, Inc. (NYSE:PBYI) has declined 77.02% since January 12, 2018 and is downtrending. It has underperformed by 77.02% the S&P500. Some Historical PBYI News: 16/03/2018 – PUMA ENERGY CASH FLOW FROM OPERATIONS DROPS TO $477M IN 2017; 20/03/2018 – Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced; 29/05/2018 – Phase lll lMpower130 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to; 15/05/2018 – Rexahn Phase 2a Combination Study of RX-3117 and Abraxane in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage; 03/04/2018 – Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin; 30/04/2018 – PUMA EXPLORATION, TREVALI MINING SIGN OPTION PACT FOR MURRAY; 20/03/2018 – Puma sets 2022 targets to lift profits, sales; 15/05/2018 – Puma Biotechnology at Bank of America Conference Tomorrow; 20/03/2018 – Puma Expects Currency Adjusted Consolidated Net Sales Growth Around 10% Per Year Until 2022; 15/05/2018 – Rexahn Pharm: SMC Confirmed Combination of RX-3117 and Abraxane Is Safe and Well Tolerated
Carlton Hofferkamp & Jenks Wealth Management Llc decreased its stake in Nike Inc Class B (NKE) by 59.33% based on its latest 2018Q3 regulatory filing with the SEC. Carlton Hofferkamp & Jenks Wealth Management Llc sold 17,653 shares as the company’s stock declined 11.68% with the market. The institutional investor held 12,099 shares of the consumer non-durables company at the end of 2018Q3, valued at $1.03 million, down from 29,752 at the end of the previous reported quarter. Carlton Hofferkamp & Jenks Wealth Management Llc who had been investing in Nike Inc Class B for a number of months, seems to be less bullish one the $119.67 billion market cap company. The stock decreased 0.50% or $0.38 during the last trading session, reaching $76.04. About 10.69M shares traded or 34.81% up from the average. NIKE, Inc. (NYSE:NKE) has risen 19.65% since January 12, 2018 and is uptrending. It has outperformed by 19.65% the S&P500. Some Historical NKE News: 09/04/2018 – Nike Buys Computer Vision Firm Invertex; 04/04/2018 – Highsnobiety: A Virgil Abloh x Nike Air Force 1 Low Could Drop This Year; 04/04/2018 – Nike exec says co needs to step up promotion of women, minorities; 15/05/2018 – AmericnStatesman: Trae Young being courted by Nike, Adidas, Under Armour and….Puma?; 29/05/2018 – Tennis-Royal wedding guest Serena blushes at timing of “Queen is back” ad; 22/03/2018 – NIKE, BUYS DATA ANALYTICS LEADER ZODIAC; 09/04/2018 – NIKE INC SAYS HAS ACQUIRED INVERTEX LTD, A COMPUTER VISION FIRM BASED IN TEL AVIV, ISRAEL; 06/03/2018 – Trump’s China Levy Threat Puts Walmart, Nike Suppliers on Notice; 23/05/2018 – The NFL and Nike have signed a giant 10-year deal with online retailer Fanatics; 22/03/2018 – Nike Acquires Customer Data Analytics Company Zodiac — MarketWatch
Among 14 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 8 have Buy rating, 2 Sell and 4 Hold. Therefore 57% are positive. Puma Biotechnology Inc had 73 analyst reports since August 27, 2015 according to SRatingsIntel. Barclays Capital maintained it with “Overweight” rating and $122 target in Friday, November 10 report. The stock has “Buy” rating by Cowen & Co on Thursday, November 9. As per Friday, November 10, the company rating was maintained by Credit Suisse. The firm earned “Sector Perform” rating on Friday, November 10 by RBC Capital Markets. The stock has “Buy” rating by UBS on Monday, April 11. On Wednesday, September 27 the stock rating was maintained by Credit Suisse with “Buy”. As per Thursday, August 27, the company rating was initiated by JP Morgan. The firm has “Buy” rating given on Wednesday, September 21 by Stifel Nicolaus. Cowen & Co maintained the shares of PBYI in report on Monday, June 5 with “Buy” rating. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) earned “Buy” rating by Stifel Nicolaus on Wednesday, January 24.
Investors sentiment decreased to 0.99 in 2018 Q3. Its down 0.33, from 1.32 in 2018Q2. It turned negative, as 29 investors sold PBYI shares while 39 reduced holdings. 19 funds opened positions while 48 raised stakes. 33.41 million shares or 10.98% less from 37.53 million shares in 2018Q2 were reported. Tennessee-based First Mercantile Company has invested 0.01% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Partner Fund Mngmt Lp, a California-based fund reported 1.85 million shares. California State Teachers Retirement System owns 44,551 shares or 0% of their US portfolio. Boston Advsrs Ltd Limited Liability Company holds 0.03% or 15,105 shares. Jennison Ltd Liability stated it has 488,418 shares or 0.02% of all its holdings. Advisory Services Networks Ltd Liability Com accumulated 100 shares. Jane Street Gru Ltd Company holds 0% or 16,944 shares in its portfolio. Rice Hall James And Assoc Limited Liability has 238,999 shares for 0.39% of their portfolio. 112,936 were accumulated by Deutsche Bankshares Ag. Orbimed Advsrs Limited Com holds 1.49% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 2.71M shares. Fmr Limited Liability owns 1.38M shares for 0.01% of their portfolio. Partner Investment Mgmt LP owns 25,676 shares or 0.9% of their US portfolio. Mackay Shields Limited Liability invested in 12,407 shares or 0% of the stock. Numerixs Investment Technology holds 0% or 200 shares. Walleye Trading Lc, Minnesota-based fund reported 6,086 shares.
Analysts await Puma Biotechnology, Inc. (NASDAQ:PBYI) to report earnings on March, 7. They expect $-0.99 EPS, up 42.11% or $0.72 from last year’s $-1.71 per share. After $-0.37 actual EPS reported by Puma Biotechnology, Inc. for the previous quarter, Wall Street now forecasts 167.57% negative EPS growth.
Emerald Mutual Fund Advisers Trust, which manages about $1.06B and $2.96B US Long portfolio, upped its stake in Aimmune Therapeutics Inc by 64,467 shares to 461,549 shares, valued at $12.59M in 2018Q3, according to the filing. It also increased its holding in Model N Inc (NYSE:MODN) by 74,900 shares in the quarter, for a total of 672,049 shares, and has risen its stake in Freshpet Inc (NASDAQ:FRPT).
Since July 20, 2018, it had 0 buys, and 8 insider sales for $1.04 million activity. $25,011 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) was sold by BRYCE RICHARD PAUL. EYLER CHARLES R also sold $25,011 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) on Thursday, January 3. 1,839 shares were sold by Lo Steven, worth $95,360 on Friday, July 20.
More notable recent Puma Biotechnology, Inc. (NASDAQ:PBYI) news were published by: 247Wallst.com which released: “Can Puma Biotechnology Break In to Europe? – 24/7 Wall St.” on June 26, 2018, also Nasdaq.com with their article: “Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales – Nasdaq” published on August 10, 2018, Nasdaq.com published: “Incyte (INCY) to Report Q3 Earnings: What’s in the Cards? – Nasdaq” on October 24, 2018. More interesting news about Puma Biotechnology, Inc. (NASDAQ:PBYI) were released by: Nasdaq.com and their article: “ETF Preview: ETFs, Futures Lower as Wall Street Focuses More on US-China Trade Talks; Digests CPI Data – Nasdaq” published on January 11, 2019 as well as Nasdaq.com‘s news article titled: “Oversold Conditions For Puma Biotechnology (PBYI) – Nasdaq” with publication date: May 10, 2018.
More notable recent NIKE, Inc. (NYSE:NKE) news were published by: Benzinga.com which released: “ConAgra Foods, Inc. (NYSE:CAG), Nike, Inc. (NYSE:NKE) – Potential Rally in Stocks Seems to Be Kept in Check by Worries About Govt. Shutdown, Fed – Benzinga” on December 21, 2018, also Seekingalpha.com with their article: “Nike taps Coca-Cola vet to head Converse – Seeking Alpha” published on December 21, 2018, Benzinga.com published: “Wedbush: Nike (NYSE:NKE) Has Upside Potential Heading Into 2019 – Benzinga” on December 14, 2018. More interesting news about NIKE, Inc. (NYSE:NKE) were released by: Benzinga.com and their article: “Nike, Inc. (NYSE:NKE) – Nike’s North American Sales Have Been Rebounding, But Now Analysts Are Concerned About International – Benzinga” published on December 18, 2018 as well as 247Wallst.com‘s news article titled: “Why Nike Is Fridayâ€™s Big Earnings Winner – 24/7 Wall St.” with publication date: December 21, 2018.
Analysts await NIKE, Inc. (NYSE:NKE) to report earnings on March, 28. They expect $0.63 EPS, down 7.35% or $0.05 from last year’s $0.68 per share. NKE’s profit will be $991.50 million for 30.17 P/E if the $0.63 EPS becomes a reality. After $0.52 actual EPS reported by NIKE, Inc. for the previous quarter, Wall Street now forecasts 21.15% EPS growth.
Among 45 analysts covering Nike Inc. (NYSE:NKE), 29 have Buy rating, 2 Sell and 14 Hold. Therefore 64% are positive. Nike Inc. had 276 analyst reports since July 29, 2015 according to SRatingsIntel. JP Morgan maintained NIKE, Inc. (NYSE:NKE) rating on Wednesday, September 28. JP Morgan has “Overweight” rating and $61 target. The rating was maintained by Stifel Nicolaus on Thursday, December 14 with “Buy”. FBR Capital maintained the shares of NKE in report on Friday, June 30 with “Hold” rating. The firm has “Overweight” rating by JP Morgan given on Monday, March 21. The stock of NIKE, Inc. (NYSE:NKE) has “Overweight” rating given on Friday, December 21 by JP Morgan. Credit Suisse maintained NIKE, Inc. (NYSE:NKE) on Wednesday, June 29 with “Outperform” rating. BB&T Capital upgraded the stock to “Buy” rating in Monday, October 19 report. As per Wednesday, September 26, the company rating was maintained by Deutsche Bank. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, June 29 report. As per Monday, December 28, the company rating was maintained by DA Davidson.
Investors sentiment decreased to 0.82 in 2018 Q3. Its down 0.01, from 0.83 in 2018Q2. It worsened, as 48 investors sold NKE shares while 496 reduced holdings. 126 funds opened positions while 322 raised stakes. 969.47 million shares or 1.35% less from 982.71 million shares in 2018Q2 were reported. Shamrock Asset Mngmt Limited holds 0.01% or 200 shares in its portfolio. Brinker Cap holds 0.25% or 82,541 shares. New York-based Laurion Capital Limited Partnership has invested 0% in NIKE, Inc. (NYSE:NKE). National Bank Of Stockton holds 0.43% or 10,130 shares. Envestnet Asset Mgmt Inc reported 394,585 shares. Johnson Fincl Grp Inc invested in 0.03% or 3,388 shares. Burke And Herbert Bancorp And Company reported 4,411 shares. Finemark Comml Bank & Tru has 127,745 shares. Saybrook Cap Nc reported 6,208 shares. Busey Co holds 1.37% or 174,331 shares in its portfolio. Shelton reported 20,268 shares. Charter Trust Comm accumulated 51,578 shares. Silvercrest Asset Gp Limited Liability Corporation stated it has 0.04% in NIKE, Inc. (NYSE:NKE). The California-based Cap Investors has invested 1.34% in NIKE, Inc. (NYSE:NKE). Btim invested in 1.34% or 1.15M shares.
Carlton Hofferkamp & Jenks Wealth Management Llc, which manages about $218.19 million and $162.95 million US Long portfolio, upped its stake in Coca Cola Company (NYSE:KO) by 18,501 shares to 34,127 shares, valued at $1.58 million in 2018Q3, according to the filing.